IMPORTANT CORRECTION OF INVESTIGATIONAL DRUG INFORMATION

On February 11, 2022, CytoDyn, Inc. received a Warning Letter from the U.S. Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion in which FDA asserted that statements made in a video created a misleading impression regarding the safety and efficacy of leronlimab.  Leronlimab is an investigational drug that has not been approved (or authorized) by the U.S. FDA for the treatment of COVID-19 or for any indication.  For more information, click here to access a Dear Healthcare Provider (DHCP) Letter: View Here.

Contact

Get In Touch With Us


Address

1111 Main Street
Suite 660
Vancouver, WA 98660

Phone & Fax

Tel: 360-980-8524
Fax: 360-799-5954

Email

info@cytodyn.com

Business Development

Name
Scott A. Kelly, M.D.

Phone
404-229-6606

Email
skelly@cytodyn.com

Stock Transfer Agent

Address
Computershare
c/o Shareholder Services
P.O. Box 505002
Louisville, KY 40233-5002

Phone
800-962-4284
Overnight correspondence should be sent to:

Address
Computershare
c/o Shareholder Services
462 South 4th Street
Suite 1600
Louisville, KY 40202

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

*Required fields